Completed PHASE1 INTERVENTIONAL 2-arm NCT02473627

A PHASE 1, OPEN-LABEL, CROSS-OVER, FIXED SEQUENCE STUDY TO EVALUATE THE EFFECT OF MULTIPLE DOSES OF DS-1971A ON THE SINGLE DOSE PHARMACOKINETICS OF PROBE SUBSTRATES FOR CYP2B6, CYP2C8, CYP2C9, CYP2C19 AND CYP3A4 ENZYMES IN HEALTHY MALE AND FEMALE SUBJECTS

Sponsor: Daiichi Sankyo

Conditions Healthy

Interventions Buproprion DS-1971a Omeprazole Pioglitazone hydrochloride Tolbutamide midazolam hydrochloride

Updated 7 times since 2017 Last updated: Nov 4, 2015 Started: May 31, 2015 Primary completion: Jul 31, 2015 Completion: Jul 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Healthy, this trial is completed. The trial is conducted by Daiichi Sankyo and has accumulated 7 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Mar 2024 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — Mar 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Sep 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Sep 2017 [monthly]

Completed PHASE1

First recorded

May 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Daiichi Sankyo

Data source: Daiichi Sankyo

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• London, United Kingdom